Within the isolated CD8+ TIL populations, we identified different phenotypes according to expression of the co-inhibitory receptors PD-1 and CTLA-4, the tumor-antigen specificity marker CD39 and the activation marker CD137 (Figure 5A). This evidence concerns the gene TNFRSF9 and neoplasm.